Background Recommendations for adjuvant treatment for postoperative, early-stage endometrial cancer varies from observation through vaginal brachytherapy alone to pelvic radiation. While observation alone can lead to recurrence, external radiotherapy has increased morbidity. The aim of this study is to show our results with vaginal brachytherapy alone using a multichannel applicator for treatment of early-stage endometrial cancer. Materials and methods Consecutive patients undergoing vaginal brachytherapy alone following surgery for early-stage endometrial cancer were examined. A Miami multichannel vaginal brachytherapy applicator was used to deliver HDR brachytherapy in 62 patients from May 2013 to June 2018. CT scan-based images guided planning. A dose of 5.5–6.5 Gy × 4 fractions was prescribed 5 mm from the surface of the applicator. Results At a median follow up of 19 months (6–48 months), 93% of patients treated were alive with no recurrence. Two patients had only local recurrence, and 1 was salvaged with external radiotherapy and chemotherapy. There was only one nodal failure and 2 distant failures. There was no grade 2 or higher vaginal, gastrointestinal or genitourinary toxicity. Conclusion Vaginal brachytherapy alone using a multichannel applicator can be considered for early-stage endometrial cancers without compromising outcomes.

Aims: 1. To evaluate the prognostic value of SpO2 in cancer patients 2. To correlate between daily SpO2 values and tumor response to radiation. Background: Tumor hypoxia is an important prognostic factor in Oncology. It plays an important role in tumorogenesis, radiation resistance and tumor progression. Many invasive and in-vitro methods are available to assess the hypo-oxygenated status of tumors. Objective: We evaluated if SpO2 values measured from pulse oximetry could be used as an adjunct prognostic and predictive factor in oncology patients. Methods: Ten consecutive patients with locally advanced, non-metastatic disease were evaluated. Daily SpO2 measurements throughout the treatment and weekly haemoglobin values were noted. All patients received radical intent radiation therapy. Patients were categorised into two groups: poor SpO2 (<97mmHg) and better SpO2 (≥98mmHg). Results: Tumour response was higher in patients with better SpO2 (≥98mmHg). Patients with poor SpO2 (<97mmHg) presented with bulkier disease at diagnosis. Conclusion: Role of SpO2 as a prognostic and predictive factor should be explored further with in vitro and pH studies.

No abstract